QIAGEN N.V.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 24.0
- Dividend yield
- 0.54%
About Qiagen
Biological Products, (No Diagnostic Substances), SIC 2836
QIAGEN provides sample and assay technologies that isolate, purify, and analyze biological materials to deliver molecular insights. The company supplies consumable products and automated instruments across key solution areas, including sample technologies, diagnostic solutions, PCR nucleic acid amplification, and genomics or next-generation sequencing. These offerings support customers across academic research, pharmaceutical development, biotechnology sectors, and clinical diagnostic laboratories.
The enterprise maintains an international operating footprint across several geographic jurisdictions, with presence and operations identified in countries including the United States, Germany, the Netherlands, Poland, and the United Arab Emirates. It organizes activities through worldwide entities and joint ventures, with key legal and corporate establishment situated in the Netherlands.
Summary of the business section of Qiagen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- QIAGEN N.V.
- Founded
- 1984
- Headquarters
- Pl Venlo, Netherlands
- Address
- Hulsterweg 82 5912 PL
- Phone
- 31-77-35566-00
- Website
- qiagen.com
- Employees
- 5,700, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- P7
- Fiscal year ends
- December 31
- Auditor
- KPMG AG Wirtschaftsprufungsgesellschaft, Dusseldorf, Germany,
Stock & identifiers
- Ticker
- QGEN
- Exchange
- NYSE
- IPO date
- Jun 28, 1996
- Shares outstanding
- 217M, Dec 31, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 4-for-1, Jul 14, 2000; 2-for-1, Jul 16, 1999
- SEC CIK
- 1015820
- CUSIP
- N72482156
- ISIN
- USN724821566
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Qiagen's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 8, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| Apr 28, 2020 | Tender offer | Third-party tender offer for the company's shares |
| Jan 8, 2018 | Delisting | Notice of delisting from exchange (Form 25) |
| Dec 20, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 15, 2007 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jun 15, 2007 | Tender offer | Third-party tender offer for the company's shares |
| May 11, 2007 | Merger | Registration of securities for a merger or exchange offer (S-4) |